Macphee G J, Curzio J, Farish E, Reid J L, Elliott H L
Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, Scotland.
J Cardiovasc Pharmacol. 1992 Sep;20(3):429-33. doi: 10.1097/00005344-199209000-00013.
The blood pressure (BP)- and lipid-lowering activities of the alpha 1-antagonist, doxazosin, were investigated in hypertensive, hypercholesterolaemic patients. Thirty-one patients satisfactorily completed the study, and there was no significant difference between doxazosin and placebo in terms of reported adverse events. After 3-month treatment, BP was significantly reduced by doxazosin by 24/14 mm Hg supine and by 33/22 mm Hg erect as compared with corresponding reductions of 2/9 and 2/2 mm Hg with placebo. There were concomitant improvements in the plasma lipid profile with, in particular, significant net reductions of 30% for triglycerides and 20% for apoprotein B. There was no adverse effect on glucose metabolism. The principal aim of this study was assessment of the clinical utility and acceptability of doxazosin in a heterogeneous population of patients with several cardiovascular risk factors. The results confirm that doxazosin is an effective antihypertensive agent that has modest additional beneficial effects on the plasma lipid profile.
在高血压、高胆固醇血症患者中研究了α1拮抗剂多沙唑嗪的降压和降脂活性。31名患者顺利完成了研究，在报告的不良事件方面，多沙唑嗪与安慰剂之间无显著差异。治疗3个月后，多沙唑嗪使仰卧位血压显著降低24/14 mmHg，直立位血压显著降低33/22 mmHg，而安慰剂相应降低2/9和2/2 mmHg。血浆脂质谱也有相应改善，尤其是甘油三酯显著净降低30%，载脂蛋白B显著净降低20%。对葡萄糖代谢无不良影响。本研究的主要目的是评估多沙唑嗪在具有多种心血管危险因素的异质性患者群体中的临床效用和可接受性。结果证实，多沙唑嗪是一种有效的抗高血压药物，对血浆脂质谱有适度的额外有益作用。
